mRNA Skin Cancer Vaccine Shows Success as Trials Expand to Lung and Pancreatic Cancers

3 articles · Updated · The Washington Post · Sep 19

Researchers said an experimental mRNA drug that delivers personalized melanoma vaccines has shown enough success to be viewed as a potential breakthrough.
That result is fueling broader efforts to apply the same mRNA approach to other tumors by tailoring vaccines to each patient's cancer.
Trials are already underway in lung cancer, pancreatic cancer and other diseases, extending the technology beyond melanoma.
The expansion suggests mRNA—proven at scale in vaccines—could open a wider new class of personalized cancer treatments if later studies confirm the early promise.

Sources

Could the mRNA tech that conquered melanoma finally unlock a cure for the world's most notoriously untreatable 'cold' tumors?

Personalized cancer vaccines show incredible promise, but will the six-week custom manufacturing bottleneck keep this breakthrough from saving lives?

If mRNA vaccines trigger massive immune responses against cancer, why do some patients still face sudden and unexplained tumor recurrence?